Evidence map›Paper›PMID 38971921›Full record

ArticleJournal of cardiovascular translational research2024

Plasma Biomarker Screening Based on Proteomic Signature of Patients with Resistant Hypertension.

Jianmin Du, Xiaoqian Yu, Wenyu Zhang, Xinghai Zhang, Hengli Zhao, Rui Xu, Qing Wen

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianmin Du *Department of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Xiaoqian Yu *Department of Cardiology, Jinan Central Hospital, Shandong University, Jinan, 250013, China.
Wenyu ZhangDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Xinghai ZhangDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Hengli ZhaoDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China.
Rui XuDepartment of Cardiology, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China. xuruicn@hotmail.com.
Qing WenDepartment of Clinical Research Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, China. jnlcsy_stu@163.com.ORCID 0009-0003-8515-3259

Funding

Jinan Technology Development Program, China 202134049Shandong Province Medical and Health Technology Project 202313010781
6 · The paper itself

Abstract

Resistant hypertension (RH) poses a significant health challenge, yet its underlying pathogenesis remains unclear. This study employs untargeted proteomic techniques to analyze the plasma of patients with RH and controlled hypertension (CH), identifying 157 differentially expressed proteins, with TGFB1 emerging as a key candidate. Through gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment, Protein-Protein Interaction Networks (PPI) topological analysis, TGFB1's differential regulation in RH is established. ELISA verification solidifies TGFB1's role, marking it as a potential biological target for early RH diagnosis and treatment. The study underscores the importance of proteomic approaches in enhancing our understanding of RH and improving therapeutic strategies. These findings carry implications for advancing RH diagnostics and treatment modalities, addressing a critical gap in current knowledge.

Indexed as

BiomarkersDrug ResistanceHypertensionPredictive Value of TestsProtein Interaction MapsProteomicsTransforming Growth Factor beta1AgedAntihypertensive AgentsBlood PressureBlood ProteinsCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansMaleAntihypertensive AgentsBiomarkersBlood ProteinsTGFB1 protein, humanTransforming Growth Factor beta1BiomarkerControlled hypertensionResistant hypertensionTGFB1Untargeted proteomics

Identifiers

PMID38971921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.